|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of CVN058 on Mismatch Negativity in Subjects With Stable Schizophrenia
This is a phase 1, double-blind, placebo-controlled, 3 period cross-over study to evaluate CVN058 target engagement by measuring auditory evoked potential mismatch negativity (MMN) downstream to 5-hydroxytryptamine receptor 3 (5-HT3) as a pharmacodynamic (PD) marker.
100 项与 Cerevance Alpha, Inc. 相关的临床结果
0 项与 Cerevance Alpha, Inc. 相关的专利(医药)
100 项与 Cerevance Alpha, Inc. 相关的药物交易
100 项与 Cerevance Alpha, Inc. 相关的转化医学